Trending Lower

We’re doing pretty well around here, and that’s why I’m a little edgy. January was an unpleasant month, but February has been so good so far that we’re well into the black. It’s looking iffy again, and that has me ready to protect gains.

The main gain I’m worried about is Maxtor. I already sold half at $5.30 on February 11th, along with my entire UTStarcom position. Following those two trades, Maxtor rose to more than $5.90 last Thursday morning before selling off to close Friday at $5.53. I’m still a firm believer in the stock’s long-term potential, but am trading it here for the short term. Thus, I have an order in to sell a quarter of my original position (that is, half of my remaining position) at $5.50.

Selling all of UTStarcom at a 9% loss was a good move. The stock now sits at $13.53, which is 18% below my original buy price.

Last Friday, I bought shares of Sun Microsystems at $4.20. Several readers emailed to ask about the wisdom of this trade. They noted that the fundamentals of Sun are not particularly compelling. That’s true, however, they’ve never been particularly compelling and yet we’ve been able to trade it successfully in the $3.50 to $5.50 range over the past three years or so. Sun sold off prior to the rest of tech this year, and it seems to be resting at solid support in the $4.15 area. I’m not looking to hold this until I use proceeds from the sale to pay my entry fee into a long-term care center. I’m looking to sell it somewhere around $4.90 before summer. We’re not off to a very promising start, though. It closed Friday at $4.16, down 1% from $4.20.

Pfizer, on the other hand, is finally showing signs of life, proving yet again that I’m as fallible as they come. Why, you ask? Because I was just about to recommend that you buy additional shares at $25 to get an average buy price of $26.50 when, lo’ and behold, good news about the company’s Celebrex and Bextra being able to hit the market again sent the stock to a Friday close of $26.80. While we missed out on the gains from $25, we can take comfort in our original $28 buy being down a mere 4%.

The market is not looking healthy, and technology looks especially ready to take a breather. Technology is where I make most of my money, so I’ll be watching carefully. We’re lucky in that most of what we need to do is protect our gains rather than guard against losses. If only all of life’s problems could be so cherry.

This entry was posted in Uncategorized. Bookmark the permalink. Both comments and trackbacks are currently closed.
  • Here are your three options:

    Option 1: Annual Subscription (no refunds)

    For just $200 per year, you’ll receive everything listed above to completely upgrade the way you manage your investments. This is 17% cheaper than the monthly option. This is what I recommend:






    Option 2:Monthly Subscription (no refunds)

    If you'd like to try The Kelly Letter  without paying the full year, you can pay $20 per month.





    Option 3:Free Email List

    If you'd like to hear more from me but aren't ready to part with any money yet, you're welcome to join my free email list:

    Join the free list





    Thank you for the work you do. You're a household name here and my wife and I often discuss your letters on Sundays. My ten- and seven-year-old children recognize your name and will eventually be taught to invest using 3Sig and 6Sig. You've had an enormously positive impact on our investing and inspired me to look at the world in more rational and clear terms than I did years ago. I'm sure that thousands of others would say the same. Kelly Letter subscriber Matt Barnes
    Matt Barnes
    Product Line Director
    OCLC

    Join Matt and thousands of other rational investors to invest without stress.

    Subscribe to The Kelly Letter  now!

Bestselling Financial Author